세계의 직접 작용 항바이러스제 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 유형별, 적응증별, 루트별, 유통 채널별, 지역별, 경쟁별(2020-2030년)

Direct-acting Antiviral Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Indication, By Route, By Distribution Channel, By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,297,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,696,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,195,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

직접 작용 항바이러스제 세계 시장 규모는 2024년 114억 1,000만 달러로 평가되었고, 2030년까지 예측기간 동안 연평균 12.86% 성장하여 236억 1,000만 달러에 달할 것으로 예측됩니다.

세계 직접 작용 항바이러스제(DAA) 시장은 바이러스 감염, 특히 C형 간염의 확산으로 인해 확대되고 있습니다. 이러한 약물은 특정 바이러스 단백질을 표적으로 하여 복제를 억제하기 때문에 매우 효과적이고 내약성이 좋은 치료 옵션을 제공합니다. 의약품의 발전으로 효능이 향상되고 치료 기간이 단축된 차세대 DAA가 개발되고 있습니다. 의료진과 정부가 C형 간염 퇴치 프로그램을 우선순위에 두면서 시장이 크게 성장하고 있습니다. 병용요법의 도입은 치료 결과를 더욱 향상시키고, 약제 내성 위험을 줄이며, 지속적 바이러스학적 반응(SVR)을 증가시키고 있습니다. 신흥국에서의 진단 검사 및 치료 접근성 확대는 시장 확대에 중요한 역할을 하고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	114억 1,000만 달러
시장 규모 : 2030년	236억 1,000만 달러
CAGR : 2025-2030년	12.86%
급성장 부문	NS3/4 A 프로테아제
최대 시장	북미

조기 진단 및 조기 치료에 대한 인식이 높아지면서 정부의 이니셔티브와 비영리 단체의 지원을 받고 있습니다. 항바이러스제 연구에 대한 투자가 증가하면서 안전성이 개선된 혁신적인 치료법 개발이 촉진되고 있습니다. 개인 맞춤형 의료로의 전환은 더 높은 치료 성공률을 보장하는 표적 항바이러스 요법에 대한 수요에 영향을 미치고 있습니다. 생명공학 및 유전자 연구의 획기적인 발전으로 제약회사들은 보다 정밀하고 강력한 DAA를 설계할 수 있게 되었습니다. 주사 치료보다 경구 치료의 선호도가 높아짐에 따라 환자들의 순응도가 향상되어 DAA가 항바이러스 치료 전략에서 선호되는 선택이 되고 있습니다. 연구기관과 제약사의 공동연구는 의약품 개발을 촉진하고 차세대 DAAs의 강력한 파이프라인을 형성하고 있습니다. 헬스케어 인프라의 확대와 각국의 유리한 상환 정책은 시장 기업들에게 기회를 제공합니다.

이러한 진전에도 불구하고, 시장은 높은 치료 비용과 관련된 문제에 직면해 있으며, 저소득 지역의 환자들에게 접근성이 제한되어 있습니다. 약제 내성 바이러스 균주의 출현이 우려되고 있으며, 보다 효과적인 제제 개발을 위한 지속적인 연구가 필요합니다. 규제 장벽과 신규 DAA의 승인 절차에 시간이 오래 걸리기 때문에 시장 진입이 지연되어 혁신 주기에 영향을 미칠 수 있습니다. 일부 지역에서는 효과적인 항바이러스 치료제의 가용성에 대한 인식이 제한적이기 때문에 채택률이 둔화되고 있습니다. 제네릭 의약품의 존재는 시장 경쟁을 심화시켜 가격 전략을 압박하고 있습니다. 전략적 가격 책정 모델, 내성 관리 조사, 세계 치료 보급 활동 강화를 통해 이러한 문제를 해결하는 것이 시장 성장을 유지하는 데 필수적입니다.

주요 시장 성장 촉진요인

높은 효과와 치료율 향상

주요 시장 이슈

높은 치료비

주요 시장 동향

적응증 확대

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 직접 작용 항바이러스제 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 유형별(NS3/4 A 프로테아제, NS5A 단백질, NS5B RNA 의존성 RNA 폴리메라제)
  • 적응증별(C형 간염 바이러스, HIV 감염/에이즈, 인플루엔자, 예방)
  • 투여 경로(정맥내, 경구, 피하, 국소)
  • 유통 채널별(병원 약국, 소매 약국, 온라인 약국)
  • 지역별
  • 기업별(2024년)
• 제품 시장 맵
  • 약제 유형별
  • 적응증별
  • 투여 경로별
  • 유통 채널별
  • 지역별

제6장 북미의 직접 작용 항바이러스제 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 직접 작용 항바이러스제 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인

제8장 아시아태평양의 직접 작용 항바이러스제 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 일본
  • 인도
  • 호주
  • 한국

제9장 남미의 직접 작용 항바이러스제 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 직접 작용 항바이러스제 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 인수합병(M&A)
• 제품 출시

제13장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제14장 경쟁 구도

• 나트코파마 주식회사
• 바 옷감·파마슈티카르즈
• 닥터·레디즈·라보레토리즈
• 존슨·엔드·존슨
• 머크사
• 기리아드·사이엔시즈
• 앗비 주식회사
• 브리스톨·마이야즈스크이브사

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

LSH

영문 목차

영문목차

Global Direct-acting Antiviral Drug Market was valued at USD 11.41 Billion in 2024 and is expected to reach USD 23.61 Billion in the forecast period with a CAGR of 12.86% through 2030. The global direct-acting antiviral (DAA) drug market is expanding due to the increasing prevalence of viral infections, particularly hepatitis C. These drugs target specific viral proteins to inhibit replication, offering a highly effective and well-tolerated treatment option. Pharmaceutical advancements have led to the development of next-generation DAAs with improved efficacy and shorter treatment durations. The market is witnessing significant growth as healthcare providers and governments prioritize hepatitis C elimination programs. The introduction of combination therapies has further enhanced treatment outcomes, reducing the risk of drug resistance and increasing sustained virologic response (SVR) rates. Expanding access to diagnostic testing and treatment in developing countries is playing a crucial role in market expansion.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 11.41 Billion
Market Size 2030	USD 23.61 Billion
CAGR 2025-2030	12.86%
Fastest Growing Segment	NS3/4 A Protease
Largest Market	North America

The market is benefiting from increasing awareness of early diagnosis and treatment, supported by government initiatives and non-profit organizations. Rising investments in antiviral drug research are fostering the development of innovative therapies with improved safety profiles. The shift toward personalized medicine is influencing the demand for targeted antiviral therapies, ensuring higher treatment success rates. Breakthroughs in biotechnology and genetic research are enabling pharmaceutical companies to design more precise and potent DAAs. The growing preference for oral therapies over injectable treatments is driving patient adherence, making DAAs a preferred choice in antiviral treatment strategies. Collaborations between research institutions and pharmaceutical firms are expediting drug development, leading to a robust pipeline of next-generation DAAs. Expanding healthcare infrastructure and favorable reimbursement policies in various countries are creating opportunities for market players.

Despite advancements, the market faces challenges related to high treatment costs, limiting accessibility for patients in low-income regions. The emergence of drug-resistant viral strains is a growing concern, requiring continuous research to develop more effective formulations. Regulatory hurdles and lengthy approval processes for new DAAs can delay market entry, impacting innovation cycles. Limited awareness in certain regions about the availability of effective antiviral treatments is slowing adoption rates. The presence of generic alternatives is intensifying market competition, putting pressure on pricing strategies. Addressing these challenges through strategic pricing models, research in resistance management, and increased global treatment outreach will be essential for sustaining market growth.

Key Market Drivers

High Efficacy and Improved Cure Rates

In recent years, the global pharmaceutical landscape has witnessed a transformative shift in the treatment of viral infections, particularly hepatitis C, due to the advent of direct-acting antiviral drugs (DAAs). These innovative medications have demonstrated exceptional efficacy, with cure rates exceeding 95%, redefining the approach to managing viral diseases.

The high efficacy of DAAs translates into significantly improved patient outcomes. For instance, a study published in JAMA Network Open reported that among patients treated with DAAs, 97.3% achieved sustained virologic response (SVR), indicating a cure. Successful DAA therapy not only clears the virus but also halts disease progression, reducing risks of liver fibrosis, cirrhosis, and hepatocellular carcinoma.

Beyond individual benefits, DAAs contribute to public health by reducing viral transmission. Effective treatment decreases viral load, thereby lowering the likelihood of spreading infections such as hepatitis B and C, which are transmitted through routes like blood contact and sexual intercourse. The World Health Organization highlights that DAAs can cure over 95% of hepatitis C cases, yet access to diagnosis and treatment remains limited globally.

DAAs also offer shorter treatment durations compared to traditional interferon-based therapies. While older regimens required treatment courses of up to 48 weeks, DAA therapies typically range from 8 to 12 weeks, enhancing patient compliance and reducing healthcare burdens. Furthermore, DAAs are associated with improved tolerability and fewer severe side effects, encouraging patients to complete their treatment regimens.

The success of DAAs has instilled confidence among patients and healthcare providers. For example, the U.S. Department of Health and Human Services notes that new hepatitis C treatments can cure approximately 95% of patients, significantly decreasing the likelihood of severe liver complications and reducing overall healthcare costs. This underscores the importance of expanding access to these life-saving therapies to achieve broader public health benefits.

Key Market Challenges

High Treatment Costs

One of the most significant challenges is the high cost of direct-acting antiviral drugs. While these medications are highly effective, their price tags can be prohibitive for many patients, especially in low- and middle-income countries. Striking a balance between recouping research and development costs and ensuring affordable access is a persistent challenge.

Key Market Trends

Expanded Indications

One significant trend in the DAA market is the exploration of expanded indications. While DAAs have been predominantly used to treat hepatitis C and B, researchers are investigating their efficacy against other viral infections. This could lead to the development of new DAA therapies targeting a broader range of viruses.

Key Market Players

• Natco Pharma Ltd
• Vertex Pharmaceuticals Inc
• Dr Reddy's Laboratories Ltd
• Johnson & Johnson
• Merck & Co Inc
• Gilead Sciences Inc
• AbbVie Inc
• Bristol-Myers Squibb Co

Report Scope:

In this report, the Global Direct-acting Antiviral Drug Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Direct-acting Antiviral Drug Market, By Type:

• NS3/4A Protease
• NS5A Protein
• NS5B RNA-Dependent RNA polymerase

Direct-acting Antiviral Drug Market, By Indication:

• Hepatitis C Virus
• HIV Infection/ AIDS
• Influenza
• Prophylaxis

Direct-acting Antiviral Drug Market, By Route:

• Intravenous
• Oral
• Subcutaneous
• Topical

Direct-acting Antiviral Drug Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Direct-acting Antiviral Drug Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Direct-acting Antiviral Drug Market.

Available Customizations:

Global Direct-acting Antiviral Drug market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Direct-acting Antiviral Drug Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
  • 5.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
  • 5.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
  • 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Product Market Map
  • 5.3.1. By Drug Type
  • 5.3.2. By Indication
  • 5.3.3. By Route
  • 5.3.4. By Distribution Channel
  • 5.3.5. By Region

6. North America Direct-acting Antiviral Drug Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
  • 6.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
  • 6.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
  • 6.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Direct-acting Antiviral Drug Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Route
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Direct-acting Antiviral Drug Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Route
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Direct-acting Antiviral Drug Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Route
      • 6.3.3.2.4. By Distribution Channel

7. Europe Direct-acting Antiviral Drug Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
  • 7.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
  • 7.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
  • 7.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Direct-acting Antiviral Drug Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Route
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. United Kingdom Direct-acting Antiviral Drug Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Route
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. France Direct-acting Antiviral Drug Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Route
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Direct-acting Antiviral Drug Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Route
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Direct-acting Antiviral Drug Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Route
      • 7.3.5.2.4. By Distribution Channel

8. Asia-Pacific Direct-acting Antiviral Drug Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
  • 8.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
  • 8.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
  • 8.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Direct-acting Antiviral Drug Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Route
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. Japan Direct-acting Antiviral Drug Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Route
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. India Direct-acting Antiviral Drug Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Route
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. Australia Direct-acting Antiviral Drug Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Route
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. South Korea Direct-acting Antiviral Drug Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Route
      • 8.3.5.2.4. By Distribution Channel

9. South America Direct-acting Antiviral Drug Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
  • 9.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
  • 9.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
  • 9.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Direct-acting Antiviral Drug Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Route
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. Argentina Direct-acting Antiviral Drug Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Route
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. Colombia Direct-acting Antiviral Drug Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Route
      • 9.3.3.2.4. By Distribution Channel

10. Middle East and Africa Direct-acting Antiviral Drug Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
  • 10.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
  • 10.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
  • 10.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Direct-acting Antiviral Drug Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Route
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Saudi Arabia Direct-acting Antiviral Drug Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Route
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. UAE Direct-acting Antiviral Drug Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Route
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.6.1. Natco Pharma Ltd
• 14.6.2. Vertex Pharmaceuticals Inc
• 14.6.3. Dr Reddy's Laboratories Ltd
• 14.6.4. Johnson & Johnson
• 14.6.5. Merck & Co Inc
• 14.6.6. Gilead Sciences Inc
• 14.6.7. AbbVie Inc
• 14.6.8. Bristol-Myers Squibb Co

15. Strategic Recommendations

16. About Us & Disclaimer

관련자료